Multiple myeloma (MM) is one of the most common haematological cancers, with an incidence rate of 10%. As per the GLOBOCON 2022 update, the age standardised rate (ASR) of mortality was 1.1 of 100,000 people globally. The majority of MM cases originate from a precancerous asymptomatic stage known as monoclonal gammopathy of undetermined significance (MGUS) or an advanced intermediate asymptomatic stage called smoldering multiple myeloma (SMM). It is estimated that 5% of the po